Mark Atkins

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus

Management of hepatitis B

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Review article: hepatitis B and liver transplantation

Treatment predictors of a sustained virologic response in hepatitis B and C

Mechanisms of type-I- and type-II-interferon-mediated signalling

Regulation of microRNA function in animals

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Molecular diagnosis and treatment of drug-resistant hepatitis B virus

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Virologic response and resistance to adefovir in patients with chronic hepatitis B

Craniofacial morphology, head posture, and nasal respiratory resistance in obstructive sleep apnoea: an inter-ethnic comparison

Molecular imaging in living subjects: seeing fundamental biological processes in a new light

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

A robust cell culture system supporting the complete life cycle of hepatitis B virus

Hepatitis B and Hepatitis C Viruses in Liver Transplantation

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

Coinfection With HIV-1 and HCV—A One-Two Punch

Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report

Management of Hepatic Complications in HIV‐Infected Persons

Hepatitis B Virus Infection

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Management of hepatitis B: 2000—Summary of a workshop

Childhood obesity: public-health crisis, common sense cure

Sexual Transmission of HIV

Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

Long-term safety of lamivudine treatment in patients with chronic hepatitis B

Hepatitis C

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*

Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C

A randomized controlled trial of lamivudine to treat acute hepatitis B

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

Hepatitis B virus infection

Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers

Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B

Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load

Effect of virological response on post‐treatment durability of lamivudine‐induced HBeAg seroconversion

Treatment of chronic hepatitis B

Management of Hepatocellular Carcinoma *

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

Sensorineural hearing loss in children

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

Molecular Virology of Hepatitis B Virus

Hepatitis B Virus and Cancer Prevention

Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

Chronic hepatitis B

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy

Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis

Chronic hepatitis B: Update 2009 #

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Determinants for Sustained Hbeag Response to Lamivudine Therapy

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine‐resistant mutants

The development of in vivo imaging systems to study gene expression

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Ninety‐Six–Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV‐1 and Wild‐Type Hepatitis B Virus

Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens

Hepatocellular carcinoma pathogenesis: from genes to environment

Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

Infection in Solid-Organ Transplant Recipients

Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte dʼIvoire

Antiretroviral Treatment of Adult HIV Infection

Hepatitis B virus induces RNR-R2 expression via DNA damage response activation

Hepatocellular Carcinoma

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results

Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy–Naive and –Experienced Patients Coinfected with HIV‐1 and Hepatitis B Virus

The way forward in HCV treatment — finding the right path

Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Rubella

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B

Entecavir therapy for lamivudine‐refractory chronic hepatitis B

Excellent Outcome of Lamivudine Treatment in Patients With Chronic Renal Failure and Hepatitis B Virus Infection

Long-term therapy of chronic hepatitis B with lamivudine

Epidemiology of Obstructive Sleep Apnea

Risk Factors for Sleep-disordered Breathing in Children

Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B

Hepatocellular Carcinoma

Prevention of materno‐foetal transmission of hepatitis B in sub‐Saharan Africa: the evidence, current practice and future challenges

Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells

A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection

Cytokine Storm

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

A Systematic Review of the Epidemiologic Interactions Between Classic Sexually Transmitted Diseases and HIV

Anti‐viral therapy for prevention of perinatalHBVtransmission: extending therapy beyond birth does not protect against post‐partum flare

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients

Adding adefovir vs. switching to entecavir for lamivudine‐resistant chronic hepatitis B (ACE study): a 2‐year follow‐up randomized controlled trial

Fibrosis — A Common Pathway to Organ Injury and Failure

Pathophysiology of Sleep Apnea

HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

Clinical course of 161 untreated and tenofovir‐treated chronic hepatitisBpregnant patients in a low hepatitisBvirus endemic region

Overview of Castleman disease

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis

No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Prevention of Hepatitis B Recurrence after Liver Transplantation

Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.

Preventives Versus Treatments *

Increased mTOR activation in idiopathic multicentric Castleman disease

Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin

Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Persons in a Randomized, Controlled Study (CAESAR)

Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases: Fig 1

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study

Nasal Resistance in Obstructive Sleep Apnea

Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease

Combined lamivudine/interferon-α treatment in ‘immunotolerant’ children perinatally infected with hepatitis B: A pilot study

Progression of HIV disease is associated with increased expression of FcγRI and CR1 on alveolar macrophages

Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients.

Guillain-Barré syndrome associated with rubella